Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Daniel Petrylak: GU 2020 prostate picks

Daniel Petrylak • 15 Feb 2020
GU Cancers 2020
Genitourinary Cancer Prostate Cancer Antibodies Atezolizumab Cabozantinib Cediranib Checkpoint Inhibitors Olaparib
COSMIC-021

Daniel Petrylak, MD, Yale Cancer Center, New Haven, CT, discusses his research highlights from the 2020 ASCO GU meeting. Specifically mentioned was the combination of olaparib and cediranib for castrate-resistant prostate cancer and the COSMIC study, which investigated the combination of atezolizumab and cabozantinib for prostate cancer. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Daniel Petrylak

0:43
Current developments in FGFR inhibitors for urothelial cancer
Daniel Petrylak • 3 Jun 2023
1:59
How can we best sequence novel treatments in urothelial cancer?
Daniel Petrylak • 3 Jun 2023
0:24
HER2-targeting ADCs for urothelial carcinoma
Daniel Petrylak • 3 Jun 2023
1:04
THOR: erdafitinib in advanced or metastatic urothelial cancer and FGFR alterations
Daniel Petrylak • 3 Jun 2023

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals